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Abstract
Parkinson’s disease is frequently associated with depres-
sive symptoms. When depression occurs at early stages
and before the onset of characteristic motor symptoms
of the disease, differential diagnosis of major depression
may be difficult. Differences in psychopathological fea-
tures of depression in Parkinson’s disease and major
depression have been reported by some authors. This
study presents data of 49 patients with depression in Par-
kinson’s disease and 38 patients with major depression.
The severity of depressive symptoms was equivalent in
both groups. Depressive features did not differ between
the two groups with exception of affective flattening,
delusional ideas and suicide attempts. In conclusion, this
investigation gives support to the assumption of a com-
mon neurobiological origin of depression in Parkinson’s
disease and major depression.
Copyright © 2003 S. Karger AG, Basel
Introduction
Many studies have shown a higher frequency and
severity of depression in patients with Parkinson’s disease
(PD) than in other chronically disabling disorders [1–5].
In PD, the incidence of depression is estimated to be
about 40% [3, 6, 7]. Studies focusing on the clinical fea-
tures of depression in PD have reported a high frequency
of anxiety symptoms [1], a low degree of guilt and self-
reproach [8] and a relative lack of delusions and halluci-
nations [9]. The similarities between these symptoms and
those of major depression (MD) are so strong, that distin-
guishing between MD and PD is sometimes difficult [9].
To date, a direct clinical comparison of depressive symp-
toms in depression of PD and MD has not been per-
formed. However, comparisons between these groups
have been performed for cognitive functions [10] and
therapeutic strategies [11]. Here, we expand on these clin-
ical studies by comparing psychopathological symptoms
of depression in PD to those of MD. While some authors
have described differences between depression in PD and
MD, the basic hypothesis in our study was that the depres-
sive syndromes are clinically comparable and share a
common neurobiological origin. This assumption is sup-
ported by several neurobiological studies. Neuroimaging
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data, performed using transcranial sonography [12–15],
magnetic-resonance imaging [15] and positron emission
tomography [16], have indicated similarities of brain pa-
thology in PD and MD. In addition, genetic association
studies [17–20] and biochemical studies [21–24] of the
basal limbic system suggest similar changes. We asked
whether clinical findings are also similar in PD with
depression and MD according to the overlapping neuro-
biological findings. The underlying concept is based on
the assumption of basal limbic system alterations in MD
as well as in depression in PD.
Methods
Subjects
Forty-nine patients with depression and PD (mean age 64 B 8
years, 31 female, 18 male) and 38 patients with MD (mean age 60 B
16 years, 24 female, 14 male) were examined. There were no signifi-
cant differences in age or gender between the groups.
Patients with PD and depression and patients with MD were
recruited from two neurological hospitals (Würzburg and Biskirchen)
and two psychiatric hospitals (Würzburg and Homburg/Saar). All
patients with MD fulfilled the diagnostic criteria according to the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
[25]. Only inpatients were included in the study. Patients were ini-
tially screened for their willingness to participate in the psychiatric
interview and were included after clinical stabilization and partial
remission. Patients with a history of relevant substance abuse, signif-
icant head trauma, inflammatory or neoplastic central nervous sys-
tem disorder, severe somatic disorder (e.g. carcinoma, instable car-
diac disease) or dementia (Mini-Mental-State Examination score
!25) were excluded. At the time of examination, 2 of the MD
patients and 5 of the PD patients were almost completely remitted.
PD patients were not examined in ‘off’ phases. All patients included
in the PD group fulfilled the British PD Brain Bank criteria [26] and
the diagnostic criteria of an ‘affective disorder in concomitant medi-
cal disorder’ (DSM-IV: 293.83). All PD patients were submitted to a
thorough neurological investigation including the Unified Parkin-
son’s Disease Rating Scale (UPDRS) [27]. The severity of PD was
classified according to Hoehn and Yahr (1967).
Psychiatric Assessment
After giving informed consent according to the Declaration of
Helsinki, patients with either MD or depression and PD were inter-
viewed by one of the two psychiatrists who investigated the patients
of both groups. The psychiatric examination comprised a detailed
semistructured interview based partly on the diagnostic criteria of
DSM-IV. To exclude significant differences in the actual depressive
state between the two patient groups, the following instruments and
self-assessment rating scales were applied: Hamilton Rating Scale for
Depression (HAMD) [28, 29], Beck Depression Inventory (BDI)
[30–32], Befindlichkeits-Skala (Bf-S) [33], Brief Psychiatric Rating
Scale (BPRS) [34], Clinical Global Impression Scale (CGI) [35],
Snaith-Hamilton Pleasure Scale, German Version (SHAPS-D) [36].
The semistructured interview assessed the following central de-
pressive symptoms: depressed mood, anxiety, anhedonia, hopeless-
Table 1. Frequency of occurrence of depressive symptoms in pa-
tients with depression and PD (PD) and with major depression (MD)
according to the semistructured interview in percent of the whole
group interviewed (n.s. = not significant)
Symptom PD, % MD, % U-test
Depressed mood 100 100 n.s.
Anxiety 73 76 n.s.
Anhedonia 94 92 n.s.
Hopelessness 88 84 n.s.
Loss of energy 100 100 n.s.
Loss of drive 86 95 n.s.
Feelings of guilt 51 55 n.s.
Worthlessness 59 58 n.s.
Formal thought disorders 86 79 n.s.
Suicidal thoughts 76 76 n.s.
Irritability 39 16 n.s.
Inner restlessness 73 50 n.s.
Affective flattening 39 76 p ! 0.003
Delusions 2 47 p ! 0.001
Suicide attempts 4 42 p ! 0.001
ness, affectiveflattening, irritability, loss of interest, loss of energy,
loss of drive, formal thought disorders, inner restlessness, delusions,
feelings of guilt, feelings of worthlessness, suicidal thoughts and sui-
cide attempts. To obtain the complete history of depression for each
patient, patients were asked to report on the current as well as on
previous depressive phases. The severity of depressive symptoms
were graded on a 5-point scale by the two psychiatrists and assessed
as being absent or existing in a relevant dimension.
Statistical Evaluation
Descriptive statistics are given as mean B SD. Inter-group com-
parison was performed using the Mann-Whitney U-test. Sequential
adjustment according to Bonferroni was performed on the data given
in table 1 because of multiple testing. Differences were assumed to be
significant for p values !0.05.
Results
The characteristics of PD patients were as follows: the
mean duration of PD was 8.5 B 5.7 years. 27 patients
showed a hypokinetic/rigid type and 22 an equivalent
type of PD. No depressive PD patients had a tremor type
of PD. According to Hoehn and Yahr, 18 patients were
classified as grade II, 10 as grade II–III, 18 as grade III,
and 3 as grade IV. Mean UPDRS scores were 5.2 B 2.2
for part I (neuropsychological functions), 14.0 B 6.6 for
part II (activities of daily living), 32.2 B 8.9 for part III
(motor examination) and 3.7 B 3.4 for part IV (complica-
tions of therapy). 54% of the PD patients suffered from
Depression in Parkinson’s Disease and
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depressive symptoms more than 1 year before the diagno-
sis of PD, 48% of the PD patients described an associa-
tion between the severity of motor function and depres-
sive symptoms during the day.
All PD patients received optimized medical treatment
for the parkinsonian symptoms. Also, 9 PD patients were
on antipsychotic drugs due to transient psychotic epi-
sodes. Because of delusional symptoms, 6 MD patients
received low-dose neuroleptic medication. Most patients
(31 of 49 with PD and 36 of 38 with MD) were treated
with antidepressant medication at the time of investiga-
tion. The antidepressive medication is summarized in
tables 2 and 3.
Comparison of depressive symptoms, as assessed by
the different instruments, showed no difference between
the groups concerning the current state of mood (table 4).
However, the semistructured interviews, which assessed
both the current and past symptoms of mood, did show
differences in the frequency of occurrence of symptoms:
More patients with PD described symptoms of irritability
and inner restlessness than patients with MD. Significant-
ly more patients with MD exhibited affective flattening,
delusions and suicide attempts (table 1). Only 2 PD pa-
tients had a history of suicide attempts; both showed
some atypical traits. One patient attempted suicide after
an ischemic stroke. However, the depressive disorder had
occurred before the ischemic event. The other patient suf-
fered from depressive episodes accompanied by a suicide
attempt several decades before PD was diagnosed. PD
patients usually do not describe the typical ‘endogenous’
signs of MD, such as cyclic variation during the day and
distinct episodes of several weeks or months. Instead, they
describe a variation of depression severity that correlates
with motor function.
However, there are many similarities. In this study, no
difference in the occurrence of depressed mood, anxiety,
anhedonia, hopelessness, loss of energy and drive, feelings
of guilt and worthlessness, formal thought disorders (cir-
cling of thoughts), and suicidal thoughts was observed.
Discussion
As shown in many studies, depression frequently ac-
companies PD, but obviously, it does not occur equally in
all types of PD. Depression seems to occur in PD patients
suffering either from the hypokinetic/rigid type or from
the hypokinetic/rigid type with tremor, but is less com-
mon in patients suffering predominantly from tremor.
This is in line with previous reports [37, 38]. These find-
Table 2. Antidepressive medication of patients with major depres-
sion. A combination of two antidepressant drugs was given to 6
patients, 1 of whom received a combination of three antidepressant
drugs
Drug Patients
treated
Dose range
mg
Mean dose
mg
Amitriptyline 7 50–250 128
Doxepine 5 80–225 156
Clomipramine 4 50–225 137
Maprotiline 3 75–125 108
Nortriptyline 1 45 45
Mirtazapine 15 15–60 42
Venlafaxine 7 75–225 160
Reboxetine 1 10 10
No antidepressant 3 – –
Table 3. Antidepressive medication of Parkinson’s patients with
depression. A combination of two antidepressant drugs was given to
5 patients
Drug Patients
treated
Dose range
mg
Mean dose
mg
Amitriptyline 11 10–150 65
Clomipramine 4 37.5–75 53
Doxepine 3 75–100 91
Maprotiline 2 50–150 100
Fluoxetine 1 40 40
Citalopram 2 10–20 15
Sertraline 3 50 50
Fluvoxamine 2 100 100
Mirtazapine 3 30–45 35
Venlafaxine 2 37.5–75 56
Hypericum extracts 3 – –
No antidepressant 18 – –
Table 4. Mean and standard deviation of rating scales in PD and
depression and MD
Scale PD and
depression
MD U-test
HAMD 17.7B7.2 18.3B7.6 p = 0.7
BDI 18.7B9.3 17.2B11.1 p = 0.2
Bf-S 29.1B11.0 30.3B14.6 p = 0.4
BPRS 42.3B6.8 39.5B7.4 p = 0.2
CGI 3.9B1.1 4.2B1.3 p = 0.3
SHAPS-D 2.3B2.3 3.0B2.9 p = 0.4
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ings support the hypothesis that depressive symptoms in
PD may not merely represent a reaction to disability, but
that MD and depression in PD might share a common
pathology. The striking similarities of depressive symp-
tomatology between depressive PD and MD patients sup-
port this hypothesis. Both patient groups in this study
were representative clinical cohorts. With regard to the
mean scores of the rating instruments, the two groups
seemed to be comparable in depression severity. Nev-
ertheless, severity of depression exhibited considerable
variability within each sample. In fact, mean scores of the
rating instruments indicate a wide range of depression
severity. This variability may limit the conclusions which
can be drawn from this investigation. It might be suggest-
ed to perform additional studies on psychopathological
features in MD and PD patients with a more homogenous
range of depression severity.
A close similarity of symptoms between the two groups
according to the semistructured interview, relating to past
and present depressive pathology, was found. Similarities
in clinical symptoms correspond to the overlapping neu-
robiological findings of both entities [39–42]. We did not
observe the reduced degree of guilt and self-reproach and
increased frequency of anxiety symptoms in PD patients
that was noted in other studies [1, 8, 43, 44]. However, in
these studies the two disorders were not directly com-
pared. In our study, only symptoms of irritability and
inner restlessness seemed slightly more prominent in PD
patients, but this did not reach statistical significance.
These increases might be due to the impairment of move-
ment initiation and performance, and the subsequent
involvement of the dopaminergic system. A disturbed
dopaminergic system could also be a reason for the asso-
ciation of motor function and depressive symptoms dur-
ing the day in PD patients. Consistent with previous
reports, we found that many patients suffer first from
depressive episodes before the clinical manifestation of
PD [45]. At this stage, no clinical signs indicate that the
affected patient will eventually develop PD; therefore an
‘endogenous’ type of depression is often suspected.
A statistically significant decrease was found only in
affective flattening, delusional ideas and suicide attempts
in PD patients as compared to MD patients. This con-
firms a previous report that depressive patients with PD
have a lower frequency of delusions [9]. It has also been
noticed that in spite of a high frequency of suicidal idea-
tion, depressive PD patients rarely perform suicide [3,
46]. The reason for these important differences is not yet
understood. It may be related to differences in severity of
depression. Neither affective flattening, delusional ideas,
nor suicide attempts are specific depressive features and
the observed difference between the two groups in this
regard seems to be of little relevance.
In conclusion, psychopathological features of depres-
sion in patients with MD and depressed PD patients were
found to be quite similar. The similarities in psychopa-
thological symptomatology as demonstrated in this study
as well as the parallels in biochemical, genetic, histological
and neuroimaging findings implicate a common pathoge-
netic basis of MD and depression in PD. The difference in
some aspects of symptomatology otherwise suggests that
there might be some additional pathogenetic factors ac-
counting for the characteristics of both groups. The
present study gives support to the hypothesis that depres-
sion in PD is not a distinct subtype of depressive disor-
ders. The overlapping psychopathological features are in
line with a common neurobiological origin of depression
in PD and MD.
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